I agree with the opinion that PFE does not consider Embeda a blockbuster drug candidate in the pain therapeutics space. The $3.6 billion object of PFE's affections would would still seem to be the Oradur drug candidates. However, an additional clinical trial and a second abuse liability study constitute the "path forward". I think its obvious that what PFE is up to: renegotiate a more favorable royalty deal with PTIE as an inducement for PFE's expenditure of the drug development funds required to bring Remoxy et al onto the market.
PTIE, as per usual, has been singularly uncommunicative. DRRX, however, in its May 10 SEC filing has been much more candid about what is going on. To wit:
"We understand form Pfizer that additional clinical studies are necessary and include, in part, a pivotal bioequivalence study with the modified formulation to bridge to the clinical data conducted with the original formulation, as well as an abuse liability study with the modified Remoxy formulation."
In sum, PTIE finds itself between a rock and a hard place vis a vis PFE. The "path forward" is obviously arduous, protracted (two years plus) and very costly (two new clinicals the outcome of which are unknown) . Barbier has no choice other than a compromise acceptable to PFE.
Since there is a clear path forward with the new abuse resistant labeling requirements it would be even better if Endo picked it up instead since their abuse resistance doesn't appear to work. Everything is about money with these companies. I still wouldn't be surprised to see Pfizer buy out Pain Therapeutics or their compounds. The information that they released via email in May was to push the PTIE stock down which worked temporarily.